Annika Malmström

3.5k total citations · 1 hit paper
66 papers, 2.3k citations indexed

About

Annika Malmström is a scholar working on Genetics, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Annika Malmström has authored 66 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Genetics, 27 papers in Oncology and 22 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Annika Malmström's work include Glioma Diagnosis and Treatment (31 papers), Brain Metastases and Treatment (14 papers) and Breast Cancer Treatment Studies (13 papers). Annika Malmström is often cited by papers focused on Glioma Diagnosis and Treatment (31 papers), Brain Metastases and Treatment (14 papers) and Breast Cancer Treatment Studies (13 papers). Annika Malmström collaborates with scholars based in Sweden, Switzerland and United States. Annika Malmström's co-authors include Roger Henriksson, Roger Stupp, Björn Tavelin, Johan Rosell, Bjørn Henning Grønberg, Christine Marosi, Henrik Schultz, Didier Frappaz, Monika E. Hegi and Benoît Lhermitte and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Annika Malmström

66 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial

2012 866 citations Annika Malmström, Bjørn Henning Grønberg et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Annika Malmström Sweden	21	1.2k	785	720	664	533	66	2.3k
J.‐Y. Delattre France	30	1.5k 1.3×	480 0.6×	807 1.1×	756 1.1×	734 1.4×	64	3.5k
Rakesh Jalali India	26	1.0k 0.9×	605 0.8×	648 0.9×	406 0.6×	490 0.9×	147	2.4k
Antonio Silvani Italy	28	1.5k 1.3×	398 0.5×	765 1.1×	931 1.4×	944 1.8×	182	3.3k
Helen Wheeler Australia	27	1.4k 1.2×	574 0.7×	590 0.8×	671 1.0×	849 1.6×	110	2.6k
Beatrice Malmer Sweden	25	831 0.7×	375 0.5×	424 0.6×	460 0.7×	713 1.3×	42	2.1k
Tony J. C. Wang United States	27	858 0.7×	421 0.5×	1.2k 1.6×	549 0.8×	555 1.0×	114	2.5k
In Ah Kim South Korea	29	617 0.5×	874 1.1×	757 1.1×	987 1.5×	1.1k 2.0×	162	3.0k
Michel Fabbro France	34	778 0.7×	511 0.7×	723 1.0×	1.1k 1.6×	658 1.2×	187	3.1k
Courtney Kromer United States	5	1.4k 1.2×	428 0.5×	505 0.7×	344 0.5×	682 1.3×	6	2.5k
R. Rampling United Kingdom	19	1.3k 1.1×	452 0.6×	681 0.9×	500 0.8×	565 1.1×	30	2.1k

Countries citing papers authored by Annika Malmström

Since Specialization

Citations

This map shows the geographic impact of Annika Malmström's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Annika Malmström with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Annika Malmström more than expected).

Fields of papers citing papers by Annika Malmström

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Annika Malmström. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Annika Malmström. The network helps show where Annika Malmström may publish in the future.

Co-authorship network of co-authors of Annika Malmström

This figure shows the co-authorship network connecting the top 25 collaborators of Annika Malmström. A scholar is included among the top collaborators of Annika Malmström based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Annika Malmström. Annika Malmström is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hegi, Monika E., Felix Boakye Oppong, James Perry, et al.. (2024). No benefit from TMZ treatment in glioblastoma with truly unmethylated MGMT promoter: Reanalysis of the CE.6 and the pooled Nordic/NOA-08 trials in elderly glioblastoma patients. Neuro-Oncology. 26(10). 1867–1875. 16 indexed citations

Coomans, Marijke B, Linda Dirven, Neil K. Aaronson, et al.. (2022). Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period. Neuro-Oncology. 24(12). 2159–2169. 13 indexed citations

Łysiak, M, et al.. (2022). The sex‐dependent role of the androgen receptor in glioblastoma: results of molecular analyses. Molecular Oncology. 16(19). 3436–3451. 6 indexed citations

Łysiak, M, Jyotirmoy Das, Annika Malmström, & Peter Söderkvist. (2022). Methylation associated with long- or short-term survival in glioblastoma patients from the Nordic phase 3 trial. Frontiers in Genetics. 13. 934519–934519. 8 indexed citations

Tavelin, Björn & Annika Malmström. (2022). Sex Differences in Glioblastoma—Findings from the Swedish National Quality Registry for Primary Brain Tumors between 1999–2018. Journal of Clinical Medicine. 11(3). 486–486. 15 indexed citations

Smits, Anja, et al.. (2021). Sex Disparities in MGMT Promoter Methylation and Survival in Glioblastoma: Further Evidence from Clinical Cohorts. Journal of Clinical Medicine. 10(4). 556–556. 13 indexed citations

Łysiak, M, Anja Smits, Elisabeth Sandberg, et al.. (2021). Deletions on Chromosome Y and Downregulation of the SRY Gene in Tumor Tissue Are Associated with Worse Survival of Glioblastoma Patients. Cancers. 13(7). 1619–1619. 9 indexed citations

Coomans, Marijke B, Martin Taphoorn, Neil K. Aaronson, et al.. (2020). Measuring change in health-related quality of life: the impact of different analytical methods on the interpretation of treatment effects in glioma patients. Neuro-Oncology Practice. 7(6). 668–675. 8 indexed citations

Malmström, Annika, et al.. (2020). “Do I want to know it all?” A qualitative study of glioma patients’ perspectives on receiving information about their diagnosis and prognosis. Supportive Care in Cancer. 29(6). 3339–3346. 9 indexed citations

10.

Malmström, Annika, M Łysiak, Ingrid Jakobsen Falk, et al.. (2019). ABCB1 single-nucleotide variants and survival in patients with glioblastoma treated with radiotherapy concomitant with temozolomide. The Pharmacogenomics Journal. 20(2). 213–219. 11 indexed citations

11.

Malmström, Annika, M Łysiak, Charlotte Bratthäll, et al.. (2019). Assessment of genetic and non-genetic risk factors for venous thromboembolism in glioblastoma – The predictive significance of B blood group. Thrombosis Research. 183. 136–142. 9 indexed citations

12.

Elsir, Tamador, Daniel Hägerstrand, Joseph W. Carlson, et al.. (2016). PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status. Oncotarget. 7(45). 72431–72442. 11 indexed citations

13.

Killander, Fredrika, Per Karlsson, H. Anderson, et al.. (2016). No breast cancer subgroup can be spared postoperative radiotherapy after breast-conserving surgery. Fifteen-year results from the Swedish Breast Cancer Group randomised trial, SweBCG 91 RT. European Journal of Cancer. 67. 57–65. 48 indexed citations

14.

Malmström, Annika, Bjørn Henning Grønberg, Christine Marosi, et al.. (2012). Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. The Lancet Oncology. 13(9). 916–926. 866 indexed citations breakdown →

15.

Wilking, Nils, Elisabet Lidbrink, Tom Wiklund, et al.. (2007). Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy. Annals of Oncology. 18(4). 694–700. 27 indexed citations

16.

Henriksson, Roger, Annika Malmström, Per Bergström, et al.. (2006). High-grade astrocytoma treated concomitantly with estramustine and radiotherapy. Journal of Neuro-Oncology. 78(3). 321–326. 18 indexed citations

17.

Sjöström, J, Juhani Collan, Kristina von Boguslawski, et al.. (2002). C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer. European Journal of Cancer. 38(4). 535–542. 36 indexed citations

18.

Stål, Olle, Åke Borg, Mårten Fernö, et al.. (2000). ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer. Annals of Oncology. 11(12). 1545–1550. 66 indexed citations

19.

Ljungman, Per, Bo Björkstrand, Tommy� Fornander, et al.. (1998). High-dose chemotherapy with autologous stem cell support in patients with responding stage IV breast cancer. Bone Marrow Transplantation. 22(5). 445–448. 9 indexed citations

20.

Kjellén, Elisabeth, R W Pero, Eva Brun, et al.. (1995). A phase I/II evaluation of metoclopramide as a radiosensitiser in patients with inoperable squamous cell carcinoma of the lung. European Journal of Cancer. 31(13-14). 2196–2202. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact